Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs

TY - JOUR

T1 - Recent Advances in Pharmacotherapy for Migraine Prevention

T2 - From Pathophysiology to New Drugs

AU - Ong, Jonathan Jia Yuan

AU - Wei, Diana Yi Ting

AU - Goadsby, Peter J.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Migraine is a common and disabling neurological disorder, with a significant socioeconomic burden. Its pathophysiology involves abnormalities in complex neuronal networks, interacting at different levels of the central and peripheral nervous system, resulting in the constellation of symptoms characteristic of a migraine attack. Management of migraine is individualised and often necessitates the commencement of preventive medication. Recent advancements in the understanding of the neurobiology of migraine have begun to account for some parts of the symptomatology, which has led to the development of novel target-based therapies that may revolutionise how migraine is treated in the future. This review will explore recent advances in the understanding of migraine pathophysiology, and pharmacotherapeutic developments for migraine prevention, with particular emphasis on novel treatments targeted at the calcitonin gene-related peptide (CGRP) pathway.

AB - Migraine is a common and disabling neurological disorder, with a significant socioeconomic burden. Its pathophysiology involves abnormalities in complex neuronal networks, interacting at different levels of the central and peripheral nervous system, resulting in the constellation of symptoms characteristic of a migraine attack. Management of migraine is individualised and often necessitates the commencement of preventive medication. Recent advancements in the understanding of the neurobiology of migraine have begun to account for some parts of the symptomatology, which has led to the development of novel target-based therapies that may revolutionise how migraine is treated in the future. This review will explore recent advances in the understanding of migraine pathophysiology, and pharmacotherapeutic developments for migraine prevention, with particular emphasis on novel treatments targeted at the calcitonin gene-related peptide (CGRP) pathway.

UR - https://www.scopus.com/pages/publications/85044181026

U2 - 10.1007/s40265-018-0865-y

DO - 10.1007/s40265-018-0865-y

M3 - Review article

AN - SCOPUS:85044181026

SN - 0012-6667

VL - 78

SP - 411

EP - 437

JO - Drugs

JF - Drugs

IS - 4

ER -